Table 2 Baseline demographic and clinical characteristics of included patients
Study name | Study groups | Total number | Age | Male (%) | BMI | SAPS II score | Respiratory rate | PaO2/FiO2 ratio | PaCO2 |
|---|---|---|---|---|---|---|---|---|---|
Yu 2017 | HFNC | 56 | 56.31 ± 7.03 | 54 | 26.32 ± 4.73 | NA | 18.43 ± 3.45 | 350 ± 33.87 | 41.73 ± 6.33 |
SO | 54 | 55.82 ± 7.92 | 52 | 25.19 ± 5.02 | NA | 17.98 ± 3.87 | 341 ± 40.65 | 43.52 ± 4.93 | |
Jaber 2016 | NIV | 148 | 62.5 ± 14.5 | 78.4 | 27.2 ± 5.9 | 33.6 ± 12.8 | 28.2 + 7.7 | 201 ± 69 | 39 ± 7 |
SO | 145 | 64.4 ± 13.1 | 74.5 | 27.1 ± 6.2 | 33.4 ± 11.7 | 28.8 + 7.3 | 188 ± 71 | 37 ± 7 | |
Gupta 2016 | HFNC | 10 | NA | NA | NA | NA | NA | NA | NA |
NIV | 10 | NA | NA | NA | NA | NA | NA | NA | |
Futier 2016 | HFNC | 108 | 62 ± 12 | 56 | 25 ± 4 | NA | NA | NA | NA |
SO | 112 | 61 ± 13 | 57 | 25 ± 4 | NA | NA | NA | NA | |
Stephan 2015 | NIV | 416 | 63.9 (62.6–65.2) | 67 | 28.2 (27.6–28.7) | 28.8 (27.7–30.0) | 23.2 (22.6–24.0) | 203 (195–212) | 39.1 (38.4–39.8) |
HFNC | 414 | 63.8 (62.5–65.2) | 66 | 28.3 (27.8–28.8) | 29.0 (27.8–30.1) | 22.8 (22.1–23.5) | 196 (187–204) | 38.7 (38.1–39.4) | |
Zhu 2013 | NIV | 48 | 62 ± 10.3 | 66 | 25.3 ± 4.6 | NA | 28.3 ± 8.6 | NA | 38.9 ± 12.2 |
SO | 47 | 61 ± 12.2 | 57 | 24.4 ± 3.5 | NA | 25.4 ± 6.7 | NA | 38.3 ± 11.3 | |
Squadrone 2005 | NIV | 105 | 66 ± 9 | 68 | 26.5 ± 4.7 | 27 ± 7 | NA | 247 ± 33 | 39 ± 7 |
SO | 104 | 65 ± 10 | 62 | 26.3 ± 4.5 | 28 ± 8 | 255 ± 31 | 39 ± 5 | ||
Aurian 2001 | NIV | 24 | 58.9 ± 10 | NA | NA | 16.9 ± 5.4 | 26.25 ± 13.2 | 124 ± 50.2 | 63.9 ± 20.5 |
SO | 24 | 63 ± 9 | NA | NA | 16.8 ± 4.4 | 29.5 ± 6.9 | 111 ± 54.3 | 43.4 ± 9.3 | |
Antonelle 2000 | NIV | 20 | 45 ± 19 | 65 | NA | NA | 38 ± 3 | NA | 42 ± 10 |
SO | 20 | 44 ± 10 | 60 | NA | NA | 37 ± 1 | NA | 38 ± 10 |